JP2024503685A - Ｉ型膜タンパク質ヘテロダイマー及びその使用方法 - Google Patents

Ｉ型膜タンパク質ヘテロダイマー及びその使用方法 Download PDF

Info

Publication number
JP2024503685A
JP2024503685A JP2023542757A JP2023542757A JP2024503685A JP 2024503685 A JP2024503685 A JP 2024503685A JP 2023542757 A JP2023542757 A JP 2023542757A JP 2023542757 A JP2023542757 A JP 2023542757A JP 2024503685 A JP2024503685 A JP 2024503685A
Authority
JP
Japan
Prior art keywords
heterodimer
polypeptide
certain embodiments
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503685A5 (enExample
Inventor
アミ タミール
マーク エル． チコシンスキ
エドウィン ブレマー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kahr Medical Ltd
Thomas Jefferson University
Original Assignee
Kahr Medical Ltd
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kahr Medical Ltd, Thomas Jefferson University filed Critical Kahr Medical Ltd
Publication of JP2024503685A publication Critical patent/JP2024503685A/ja
Publication of JP2024503685A5 publication Critical patent/JP2024503685A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023542757A 2021-01-13 2022-01-13 Ｉ型膜タンパク質ヘテロダイマー及びその使用方法 Pending JP2024503685A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163136687P 2021-01-13 2021-01-13
US63/136,687 2021-01-13
US202163139331P 2021-01-20 2021-01-20
US63/139,331 2021-01-20
PCT/IL2022/050055 WO2022153307A1 (en) 2021-01-13 2022-01-13 Type i membrane proteins heterodimers and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024503685A true JP2024503685A (ja) 2024-01-26
JP2024503685A5 JP2024503685A5 (enExample) 2024-12-13

Family

ID=82447997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542757A Pending JP2024503685A (ja) 2021-01-13 2022-01-13 Ｉ型膜タンパク質ヘテロダイマー及びその使用方法

Country Status (10)

Country Link
US (1) US20240076346A1 (enExample)
EP (1) EP4277923A4 (enExample)
JP (1) JP2024503685A (enExample)
KR (1) KR20230169933A (enExample)
AU (1) AU2022208466A1 (enExample)
BR (1) BR112023013898A2 (enExample)
CA (1) CA3204707A1 (enExample)
IL (1) IL304381A (enExample)
MX (1) MX2023008351A (enExample)
WO (1) WO2022153307A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3820887A4 (en) 2018-07-11 2022-04-20 KAHR Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
CN111454369A (zh) * 2020-04-10 2020-07-28 润方(长春)生物科技有限公司 一种用于制备异二聚物蛋白质的方法
US20250051410A1 (en) * 2021-12-23 2025-02-13 Kahr Medical Ltd. Lilrb polypeptides and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
CN110128550A (zh) * 2019-05-30 2019-08-16 南京大学 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
JP2020520249A (ja) * 2017-05-08 2020-07-09 シャンハイ ジェイエムティー−バイオ テクノロジー カンパニー リミテッド 二重特異性組換えタンパク質およびその応用
WO2020146423A1 (en) * 2019-01-07 2020-07-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
WO2020242919A1 (en) * 2019-05-29 2020-12-03 Eli Lilly And Company Tigit and pd-1/tigit-binding molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2014164519A1 (en) * 2013-03-12 2014-10-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
US20220267409A1 (en) * 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
JP2020520249A (ja) * 2017-05-08 2020-07-09 シャンハイ ジェイエムティー−バイオ テクノロジー カンパニー リミテッド 二重特異性組換えタンパク質およびその応用
WO2020146423A1 (en) * 2019-01-07 2020-07-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
WO2020242919A1 (en) * 2019-05-29 2020-12-03 Eli Lilly And Company Tigit and pd-1/tigit-binding molecules
CN110128550A (zh) * 2019-05-30 2019-08-16 南京大学 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUNG L. ALICE ET AL.: "TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM", ONCOIMMUNOLOGY, vol. Vol.7, No.8, e1466769, JPN6025047347, 2018, pages 1 - 13, ISSN: 0005738253 *

Also Published As

Publication number Publication date
IL304381A (en) 2023-09-01
MX2023008351A (es) 2023-10-10
KR20230169933A (ko) 2023-12-18
WO2022153307A1 (en) 2022-07-21
AU2022208466A1 (en) 2023-08-17
BR112023013898A2 (pt) 2023-10-31
AU2022208466A9 (en) 2024-07-11
CA3204707A1 (en) 2022-07-21
EP4277923A1 (en) 2023-11-22
US20240076346A1 (en) 2024-03-07
EP4277923A4 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
JP2024503685A (ja) Ｉ型膜タンパク質ヘテロダイマー及びその使用方法
US20240010700A1 (en) Pd1-41bbl fusion protein and methods of use thereof
JP2022541742A (ja) ヘテロダイマーおよびその使用方法
AU2018205890B2 (en) A sirpalpha-41BBL fusion protein and methods of use thereof
JP7491495B2 (ja) ＳＩＲＰα－４－１ＢＢＬバリアント融合タンパク質及びその使用方法
WO2020012485A9 (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
US20230220040A1 (en) Pd1-cd70 fusion protein and methods of use thereof
RU2815515C2 (ru) ВАРИАНТЫ СЛИТОГО БЕЛКА SIRP-альфа-4-1BBL И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN116981686A (zh) I型膜蛋白异二聚体及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230912

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230911

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260414